Final growth in girls with Turner syndrome treated with growth hormone. Analysis of the international database of growth monitoring of the company “Kabi Pharmacia” (KIGS)
https://doi.org/10.14341/probl12152
Abstract
The completion of growth, which is determined in this study by slowing down the growth rate below 1 cm per year, was observed only in 15 of 640 treated with growth hormone (GH) girls with Turner syndrome (ST), information about which is included in the KIGS database. GH was administered to patients at a dose that ranged within the group within 0.3–1.0 IU / kg per week, with a multiplicity of 3 to 7 injections per week. The results of the study were presented graphically for each patient. At the beginning of GR therapy, the standard deviation index (SDS) of growth ranged from -2.4 to 1.5 compared with the standards for CT patients developed by M. Ranke. At the beginning of the study, the group indices of median, maximum and minimum SDS growth were 0.3, -2.4 and 1.5, respectively, and by the time the final growth was achieved, their increase was noted to 1.1, -1.8 and 2.7 respectively. The final growth in girls with ST ranged from 132.7 to 161.1 cm. Compared with the predicted growth calculated for each patient, changes in the final growth in the treatment of GH in combination with oxandrolone and ethinyl estradiol ranged from -0.9 to 11.9 cm (median - 5.4 cm), while in the treatment of GH in combination with ethinyl estradiol, the median indicator was 1.6 cm. For the whole group as a whole, the median of final growth was 150.4 cm, in the subgroup of patients treated with GH in combination with oxandrolone and ethinyl estradiol, 152.1 cm and in girls, receiving GH and ethinyl estradiol, 149.3 cm.
References
1. Rosenfeld R. G., Frane J., Aitie К. M. et al.//J. Pediat.— 1992,—Vol. 121,—P. 49—55.
2. Nilsson К. O., Albertsson-Wikland K., Aronson S. et al. Long-term results of combination treatment with growth hormone. Oxandrolone and Ethinyloestradiol in girls with Turner syndrome.— Amsterdam, 1993 (in press).
3. Vanderschueren-Lodeweyckx M., Massa G., Maes M. et al. // J. clin. Endocr.— 1990,—Vol. 70,—P. 122—126.
4. Rongen-Westerlaken C., van Es A., Wit J. M. et al. // Amer. J. Dis. Child.— 1992,—Vol. 146,—P. 817—820.
5. Turner Syndrome: Growth Promoting Therapies / Eds M. B. Ranke, R. G. Rosenfeld.— Amsterdam, 1991.
6. Lyon A.' J., Preece M. A., Grand D. В. If Arch. Dis. Child.— 198’5,— Vol. 60,— P. 932—935.
7. Ranke M. B., Pfluenger H., Rosendahl W. et al. // Europ. J. Pediat.— 1983,—Vol. 141,— P. 81—88.
8. Naeraa R. W., Nielsen J. // Acta paediat. scand.— 1990,—Vol. 79,—P. 182—192.
9. Karlberg J., Albertsson-Wikland K., Naeraa R. W. et al. // Collaboration with the Swedish and Deutch Study Group for GH-treatment.— 1992 (in press).
10. Sybert V. TJ/S. Pediat.— 1984,—Vol. 104,—P. 365— 369.
11. Hausler G., Schemper M., Frisch H. et al. // Turner’s Syndrome and Growth-Promoting Therapies / Eds M. B. Ranke, R. G. Rosenfeld.— Amsterdam, 1991.— P. 67—73.
12. Bernasconi S., Giovanelli G., Volta C. et al.//Ibid.— p 53-57
13. Hibi I., Tanae A., Tanaka T. et al.//Ibid.— P. 75—81.
14. Kastrup K. W. // Acta paediat. scand.— 1988.— Suppl. 343.— P. 43—46.
15. Martinez A., Heinrich J. J., Domene H. et al.//J. clin. Endocr.— 1987,— Vol. 65,— P. 253—258.
16. Brook C. G. D., Murset G., Zachmann M., Prader A. // Arch. Dis. Child.— 1974.— Vol. 49.— P. 789—795.
Review
For citations:
Albertsson-Wikland K. Final growth in girls with Turner syndrome treated with growth hormone. Analysis of the international database of growth monitoring of the company “Kabi Pharmacia” (KIGS). Problems of Endocrinology. 1994;40(4):81-86. (In Russ.) https://doi.org/10.14341/probl12152
Views:
526
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
